Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of Ferrer Internacional's CerAxon will account for one-third of all acute ischemic drug sales in 2013 and will be driven by the drug's safety profile and ease of administration. The new Pharmacor study entitled Acute Ischemic Stroke also finds that the use of combination therapies for acute ischemic stroke will contribute to market growth.

"The use of thrombolytic therapy in combination with antithrombotic drugs and new neuroprotectant drugs will expand the market, particularly in the United States," said Andrea Witt, Ph.D., analyst at Decision Resources. "However, combination therapies in Europe will not do as well because restrictions imposed by European reimbursement agencies make doctors less likely to prescribe several drugs for what they perceive to be modest therapeutic effects."

About Acute Ischemic Stroke

Ischemic stroke is the most common cause of neurological disability worldwide. Long-term disability is the most devastating and costly result of the disease. The incidence of ischemic stroke is expected to grow steadily over the next ten years in the seven major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom). Because there is no safe, effective therapy to treat ischemic stroke in the acute phase, only a fraction of patients are currently drug-treated.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Depression Market Growth Will Finally Stall as SSRIs Lose Sales to Cheaper Generics

View Now